SCHEMBL3081705

SCHEMBL3081705

Nc1ccccc1NC(=O)C=Cc1ccc(C(NCCN2CCSCC2)C(=O)Nc2ccc(C(F)(F)F)cc2)cc1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 9/20 0.84
HDAC2 Q92769 6/20 0.84
HDAC3 O15379 4/20 0.84
MAOB P27338 2/20 0.47
TRPA1 O75762 1/20 0.42
TRPM8 Q7Z2W7 1/20 0.42
HDAC4 P56524 4/20 0.42
MEF2D Q14814 2/20 0.42
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2D6 P10635 2/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41
KCNH2 Q12809 1/20 0.41
HDAC7 Q8WUI4 2/20 0.40
HDAC10 Q969S8 2/20 0.40
HDAC11 Q96DB2 2/20 0.40
HDAC8 Q9BY41 2/20 0.40
HDAC6 Q9UBN7 2/20 0.40
HDAC9 Q9UKV0 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3081701 1.00 HDAC1 (0.84) HDAC1HDAC2HDAC3MAOBTRPA1
SCHEMBL3098436 0.93 HDAC1 (0.72) HDAC1HDAC2HDAC3HDAC4MEF2D
SCHEMBL3098427 0.93 HDAC1 (0.72) HDAC1HDAC2HDAC3HDAC4MEF2D
SCHEMBL3105150 0.92 HDAC1 (0.86) HDAC1HDAC2HDAC3MAOBTRPA1
SCHEMBL3105137 0.92 HDAC1 (0.86) HDAC1HDAC2HDAC3MAOBTRPA1
SCHEMBL3082911 0.91 HDAC2 (0.70) HDAC1HDAC2HDAC3MAOBTRPA1
SCHEMBL3082918 0.91 HDAC2 (0.70) HDAC1HDAC2HDAC3MAOBTRPA1
SCHEMBL3087553 0.91 HDAC2 (1.00) HDAC1HDAC2HDAC3MAOBTRPA1
SCHEMBL3087551 0.91 HDAC2 (1.00) HDAC1HDAC2HDAC3MAOBTRPA1
SCHEMBL3102550 0.91 HDAC1 (0.69) HDAC1HDAC2HDAC3MAOBHDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2238103-A1 NOVEL N-(2-AMINO-PHENYL)-AMIDE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-10-13 EP disclosed
US-7795315-B2 N-(2-amino-phenyl)-amide derivatives HOFFMAN-LA ROCHE INC. (US) 2010-09-14 US disclosed
US-20090203681-A1 NOVEL N-(2-AMINO-PHENYL)-AMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-08-13 US disclosed
WO-2009095324-A1 NOVEL N-(2-AMINO-PHENYL)-AMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203681-A1 NOVEL N-(2-AMINO-PHENYL)-AMIDE DERIVATIVES MKI67, API5, BAD HDAC1 815/4885HDAC2 973/4885HDAC3 1401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.